CD274 and neoplasm: The observed efficacy in a low PD-L1 expression, tumor proportion score (TPS) 5%, tumor protein 53 (TP53)-co-mutated, and adenosquamous histology context aligns with prior clinical trial data (HARMONi-A/2), suggesting broad applicability across heterogeneous subgroups.